Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA7 | P43166 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896481 | 0.90 | ALDH1A1 (0.62) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL11693736 | 0.87 | LMNA (0.57) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL2292998 | 0.85 | CA12 (0.59) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL8669772 | 0.83 | CA12 (0.57) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL1353933 | 0.83 | CA12 (0.57) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL30582428 | 0.83 | LMNA (0.65) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL940578 | 0.83 | LMNA (0.65) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL28353298 | 0.83 | ALDH1A1 (0.54) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL398849 | 0.82 | CA12 (0.70) | LMNACYP1A2CYP3A4MAOACA12 | |
| SCHEMBL11573938 | 0.82 | LMNA (0.51) | LMNACYP1A2CYP3A4MAOACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161848-A | UV (ultraviolet) light-cured adhesive, preparation method and application | 苏州吉格邦新材料科技有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-118026869-A | 4-Amino isophthalic acid dimethyl ester-tetracyanobenzene eutectic crystal and preparation method and application thereof | 天津大学 | 2024-05-14 | — | — | CN | claimed |
| CN-119161848-A | UV (ultraviolet) light-cured adhesive, preparation method and application | 苏州吉格邦新材料科技有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-118026869-A | 4-Amino isophthalic acid dimethyl ester-tetracyanobenzene eutectic crystal and preparation method and application thereof | 天津大学 | 2024-05-14 | — | — | CN | disclosed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| WO-2008152142-A1 | 2 -AMINOQUINAZOLINE DERIVATIVES AND THEIR THERAPEUTIC USES | SOFTCURE PHARMACEUTICALS AB (SE) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008004798-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-01-10 | — | — | WO | disclosed |
| US-4083980-A | ANTIALLERGENS | BOEHRINGER INGELHEIM GMBH (DT) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | HIF1AN, HIF1A, VHL | LMNA 4360/4885CYP1A2 3079/4885CYP3A4 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.